Skip to main content
Tirzepatide Telehealth

A plain-spoken reading desk for the dual GIP/GLP-1 record — where the beyond-glycemia trials (sleep apnea, heart failure, fatty liver, kidney) lead, explained step by step.

What Is Tirzepatide? GLP-1 Is a Gut Hormone

Why did researchers make Tirzepatide?

Researchers made Tirzepatide to help your body manage the sugar that follows a meal. They wanted one medicine to copy a pair of gut hormones your body releases, including GLP-1. The drug also slowed hunger and helped many people lose weight.

Your gut releases those hormones. After food, both tell your pancreas to release insulin when your sugar rises. They also slow your stomach and may leave you feeling full.

A lab builds Tirzepatide as a 39-amino-acid protein. The medicine keeps the two hormone messages going longer. One shot can therefore work through the week.

The shot goes into the soft layer under your skin. At day five, roughly half the medicine remains in your body. FDA approval came for type 2 diabetes in 2022 and weight care in 2023. The FDA later approved this use when obesity came with sleep apnea rated moderate or severe. Type 1 diabetes isn’t an approved use.

What is Tirzepatide made of?

Tirzepatide is a short protein made in a lab. Its chain has 39 amino acids, which are parts of a protein. The chain imitates the pair of hormones released after food reaches your gut. One is GLP-1, which helps your pancreas respond to rising sugar.

The drug also has a small fatty part. That part helps Tirzepatide attach to albumin. This blood protein slows the medicine from leaving your body too fast.

Doctors call the time needed to remove half of one dose its half-life. Tirzepatide has a 5-day half-life, so roughly half is present on day five [1][2]. This is why one shot can work for a week.

The two natural gut hormones, including GLP-1, come from different parts of your bowel. Each hormone prompts insulin release from your pancreas only after your blood sugar rises [1]. Tirzepatide copies the GLP-1 message and the second hormone message, but your body doesn’t make the drug itself.

What is Tirzepatide made of?

Tirzepatide mechanism of action, in plain words: what does the shot do?

The Tirzepatide mechanism of action starts with two gut hormones. One is GLP-1, which guides sugar after you eat. Once food reaches your gut, the two hormones send a message to your pancreas. Your pancreas then releases insulin only after your blood sugar rises.

Tirzepatide copies the GLP-1 message and the second hormone message with one medicine. That may bring a stronger insulin reply than either hormone brings alone [1]. It helps explain why blood sugar fell in the studies.

Tests in cells kept alive outside the body compared the GLP-1 message with the second gut-hormone message. The drug produced a strong insulin reply without copying natural GLP-1 in every way [2]. Researchers use this cell result to understand the lasting effect, but it wasn’t a result measured in people.

The medicine also reduces the hormone telling your liver to release sugar. It slows your stomach and reduces hunger through the brain [1][10]. Together, those changes help explain the blood sugar and weight findings.

The stomach delay grows weaker with continued use. Early slowing also helps explain nausea and other stomach problems. Before surgery, your care team may consider whether food remains in your stomach [15].

What is Tirzepatide used for now?

By 2025, Tirzepatide had three uses approved by the FDA.

  1. Type 2 diabetes: The May 2022 approval added Tirzepatide to diet and exercise for adults. The medicine works through two gut hormones. At that time, weight loss alone was outside the label [6][7].
  1. Weight care meant to last: In November 2023, approval covered adults with a body mass index at or above 30. This number, called BMI, weighs your size against your height. A BMI of at least 27 also qualified if weight harmed their health. The SURMOUNT studies supported this use [8].
  1. Adults with obesity and sleep apnea rated moderate or severe: The FDA approved this use later. Two sleep studies supplied the main support [11][12].

Researchers also studied heart failure in 2025, fatty liver in 2024, and kidney health in 2026. The study names were SUMMIT, SYNERGY-NASH, and SURPASS-CVOT. These findings hadn’t added new approved uses when this page was written.

Tirzepatide is NOT approved for type 1 diabetes. It isn’t approved to boost sports results. A prescription is required before you can receive the medicine [7].

How is Tirzepatide different from GLP-1 drugs?

GLP-1 is a gut hormone that guides sugar after you eat. Tirzepatide copies GLP-1 and a second gut hormone, while many similar drugs copy only GLP-1 [1]. Both hormones also shape hunger and the speed at which your stomach empties.

This two-hormone action was new when Tirzepatide gained approval. A GLP-1 drug carries one natural message, while Tirzepatide carries two. You don’t need the longer medical label to follow the studies.

Why might the second message matter? In similar studies, Tirzepatide made the mice lose more weight than GLP-1 drugs. A review also found fewer gallstones than with semaglutide in obesity trials [13]. Researchers think the added hormone might help, but they don’t know for sure.

The research page explains the two messages and the study results. It marks what was shown, what was only suggested, and what remains unknown.